Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04659759 · ClinicalTrials.gov registry record
COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 105
- Enrollment target
NCT04659759: Completed study, sponsored by Thomas Jefferson University.
NCT04659759 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04659759 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 105 participants
- Enrollment target
Study Summary
This is a prospective cohort study of pregnant patients at an urban academic center diagnosed with perinatal COVID-19 infection, followed up to 6 weeks postpartum.
Primary Outcome
IgG/IgM time profile through pregnancy up to 6 weeks post partum for those exposed to COVID-19
Interventions
- BIOLOGICAL COVID-19 vaccine
- OTHER COVID-19 exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2025-08-30 |
What the finished NCT04659759 record still lists
NCT04659759 is an observational study that tracks outcomes without assigning an intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which COVID-19 vaccine is the first listed.
NCT04659759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04659759 about?
NCT04659759 is a clinical study titled "COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes". This is a prospective cohort study of pregnant patients at an urban academic center diagnosed with perinatal COVID-19 infection, followed up to 6 weeks postpartum.
What is the current status of trial NCT04659759?
This trial is currently completed. The enrollment target is 105 participants. The study started on 2020-11-17. Estimated completion is 2025-08-30.
What interventions are being tested in trial NCT04659759?
The interventions under investigation include: COVID-19 vaccine (BIOLOGICAL), COVID-19 exposure (OTHER).
Who is sponsoring clinical trial NCT04659759?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI